Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 57184 entries
Sorted by: Best Match Show Resources per page
Investigating association between second trimester maternal serum biomarkers and pre-term delivery.

Iranian journal of reproductive medicine

Sehat Z, Goshetasbi A, Taheri Amin M.
PMID: 24639737
Iran J Reprod Med. 2013 Feb;11(2):127-32.

BACKGROUND: Considering the effect of preterm delivery in morbidity and mortality of newborns, its precaution and prevention is so important.OBJECTIVE: To investigate the association between second trimester maternal serum biomarkers (Human Chorionic Gonadotropin, Alpha-fetoprotein, Non-conjugated estrogen, Inhibin A) and...

Cite
Sehat Z, Goshetasbi A, Taheri Amin M. Investigating association between second trimester maternal serum biomarkers and pre-term delivery. Iran J Reprod Med. 2013;11(2):127-32
Sehat, Z., Goshetasbi, A., & Taheri Amin, M. (2013). Investigating association between second trimester maternal serum biomarkers and pre-term delivery. Iranian journal of reproductive medicine, 11(2), 127-32.
Sehat, Zahra, et al. "Investigating association between second trimester maternal serum biomarkers and pre-term delivery." Iranian journal of reproductive medicine vol. 11,2 (2013): 127-32.
Sehat Z, Goshetasbi A, Taheri Amin M. Investigating association between second trimester maternal serum biomarkers and pre-term delivery. Iran J Reprod Med. 2013 Feb;11(2):127-32. PMID: 24639737; PMCID: PMC3941352.
Copy Download .nbib Format: NLM
Breast cancer and protein biomarkers.

World journal of experimental medicine

Gam LH.
PMID: 24520539
World J Exp Med. 2012 Oct 20;2(5):86-91. doi: 10.5493/wjem.v2.i5.86. eCollection 2012 Oct 20.

Breast cancer is a healthcare concern of women worldwide. Despite procedures being available for diagnosis, prognosis and treatment of breast cancer, researchers are working intensively on the disease in order to improve the life quality of breast cancer patients....

Cite
Gam LH. Breast cancer and protein biomarkers. World J Exp Med. 2012;2(5):86-91doi: 10.5493/wjem.v2.i5.86.
Gam, L. H. (2012). Breast cancer and protein biomarkers. World journal of experimental medicine, 2(5), 86-91. https://doi.org/10.5493/wjem.v2.i5.86
Gam, Lay-Harn. "Breast cancer and protein biomarkers." World journal of experimental medicine vol. 2,5 (2012): 86-91. doi: https://doi.org/10.5493/wjem.v2.i5.86
Gam LH. Breast cancer and protein biomarkers. World J Exp Med. 2012 Oct 20;2(5):86-91. doi: 10.5493/wjem.v2.i5.86. eCollection 2012 Oct 20. PMID: 24520539; PMCID: PMC3905586.
Copy Download .nbib Format: NLM
Novel Biomarkers for Cardio-renal Syndrome.

Electrolyte & blood pressure : E & BP

Lee SR, Jeong KH.
PMID: 23508646
Electrolyte Blood Press. 2012 Dec;10(1):12-7. doi: 10.5049/EBP.2012.10.1.12. Epub 2012 Dec 31.

Cardio-renal syndrome (CRS) is a frequent and life-threatening syndrome. It is a disorder of the heart and kidneys in which acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Acute kidney...

Cite
Lee SR, Jeong KH. Novel Biomarkers for Cardio-renal Syndrome. Electrolyte Blood Press. 2012;10(1):12-7doi: 10.5049/EBP.2012.10.1.12.
Lee, S. R., & Jeong, K. H. (2012). Novel Biomarkers for Cardio-renal Syndrome. Electrolyte & blood pressure : E & BP, 10(1), 12-7. https://doi.org/10.5049/EBP.2012.10.1.12
Lee, Sul Ra, and Jeong, Kyung Hwan. "Novel Biomarkers for Cardio-renal Syndrome." Electrolyte & blood pressure : E & BP vol. 10,1 (2012): 12-7. doi: https://doi.org/10.5049/EBP.2012.10.1.12
Lee SR, Jeong KH. Novel Biomarkers for Cardio-renal Syndrome. Electrolyte Blood Press. 2012 Dec;10(1):12-7. doi: 10.5049/EBP.2012.10.1.12. Epub 2012 Dec 31. PMID: 23508646; PMCID: PMC3597913.
Copy Download .nbib Format: NLM
Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes.

Autoimmune diseases

Aganovic-Musinovic I, Karamehic J, Zecevic L, Gavrankapetanovic F, Avdagic N, Zaciragic A, Jukic T, Grcic N, Svrakic S.
PMID: 23097694
Autoimmune Dis. 2012;2012:321614. doi: 10.1155/2012/321614. Epub 2012 Oct 11.

Autoimmune diseases occur in 3-5% of the population. Study included 30 patients with clinically diagnosed SLE and 30 healthy controls (American college of Rheumatology, 1997). SLE was diagnosed according to criteria issued in 1997 by the American College of...

Cite
Aganovic-Musinovic I, Karamehic J, Zecevic L, et al. Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes. Autoimmune Dis. 2012;2012:321614doi: 10.1155/2012/321614.
Aganovic-Musinovic, I., Karamehic, J., Zecevic, L., Gavrankapetanovic, F., Avdagic, N., Zaciragic, A., Jukic, T., Grcic, N., & Svrakic, S. (2012). Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes. Autoimmune diseases, 2012321614. https://doi.org/10.1155/2012/321614
Aganovic-Musinovic, Izeta, et al. "Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes." Autoimmune diseases vol. 2012 (2012): 321614. doi: https://doi.org/10.1155/2012/321614
Aganovic-Musinovic I, Karamehic J, Zecevic L, Gavrankapetanovic F, Avdagic N, Zaciragic A, Jukic T, Grcic N, Svrakic S. Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes. Autoimmune Dis. 2012;2012:321614. doi: 10.1155/2012/321614. Epub 2012 Oct 11. PMID: 23097694; PMCID: PMC3477525.
Copy Download .nbib Format: NLM
The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model.

ClinicoEconomics and outcomes research : CEOR

van Herick A, Schuetz CA, Alperin P, Bullano MF, Balu S, Gandhi S.
PMID: 23180970
Clinicoecon Outcomes Res. 2012;4:337-47. doi: 10.2147/CEOR.S35487. Epub 2012 Nov 09.

PURPOSE: Many patients treated for dyslipidemia do not achieve recommended cholesterol goals despite the widespread availability of effective statins. Pharmaceutical claims show a strong tendency for patients to remain on their initially assigned treatment. With computer simulations, the impact...

Cite
van Herick A, Schuetz CA, Alperin P, et al. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. Clinicoecon Outcomes Res. 2012;4:337-47doi: 10.2147/CEOR.S35487.
van Herick, A., Schuetz, C. A., Alperin, P., Bullano, M. F., Balu, S., & Gandhi, S. (2012). The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. ClinicoEconomics and outcomes research : CEOR, 4337-47. https://doi.org/10.2147/CEOR.S35487
van Herick, Andrew, et al. "The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model." ClinicoEconomics and outcomes research : CEOR vol. 4 (2012): 337-47. doi: https://doi.org/10.2147/CEOR.S35487
van Herick A, Schuetz CA, Alperin P, Bullano MF, Balu S, Gandhi S. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. Clinicoecon Outcomes Res. 2012;4:337-47. doi: 10.2147/CEOR.S35487. Epub 2012 Nov 09. PMID: 23180970; PMCID: PMC3497874.
Copy Download .nbib Format: NLM
Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life.

The open cardiovascular medicine journal

Kelishadi R.
PMID: 21804638
Open Cardiovasc Med J. 2010;4:24-9. doi: 10.2174/1874192401004020024. Epub 2010 Feb 23.

Atherogenesis starts from the fetal life, and its natural course consists of interrelations between traditional risk factors and inflammatory, immune, and endothelial biomarkers. Even the early-stages of atherosclerotic lesions, i.e. fatty streaks present the features of chronic inflammation. Markers...

Cite
Kelishadi R. Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life. Open Cardiovasc Med J. 2010;4:24-9doi: 10.2174/1874192401004020024.
Kelishadi, R. (2010). Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life. The open cardiovascular medicine journal, 424-9. https://doi.org/10.2174/1874192401004020024
Kelishadi, Roya. "Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life." The open cardiovascular medicine journal vol. 4 (2010): 24-9. doi: https://doi.org/10.2174/1874192401004020024
Kelishadi R. Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life. Open Cardiovasc Med J. 2010;4:24-9. doi: 10.2174/1874192401004020024. Epub 2010 Feb 23. PMID: 21804638; PMCID: PMC2840608.
Copy Download .nbib Format: NLM
Clinical asthma phenotypes and therapeutic responses.

ISRN pediatrics

Zedan M, Attia G, Zedan MM, Osman A, Abo-Elkheir N, Maysara N, Barakat T, Gamil N.
PMID: 23606983
ISRN Pediatr. 2013 Mar 31;2013:824781. doi: 10.1155/2013/824781. Print 2013.

Asthma is a heterogeneous disease that means not all asthmatics respond to the same treatment. We hypothesize an approach to characterize asthma phenotypes based on symptomatology (shortness of breath (SOB), cough, and wheezy phenotypes) in correlation with airway inflammatory...

Cite
Zedan M, Attia G, Zedan MM, et al. Clinical asthma phenotypes and therapeutic responses. ISRN Pediatr. 2013;2013:824781doi: 10.1155/2013/824781.
Zedan, M., Attia, G., Zedan, M. M., Osman, A., Abo-Elkheir, N., Maysara, N., Barakat, T., & Gamil, N. (2013). Clinical asthma phenotypes and therapeutic responses. ISRN pediatrics, 2013824781. https://doi.org/10.1155/2013/824781
Zedan, M, et al. "Clinical asthma phenotypes and therapeutic responses." ISRN pediatrics vol. 2013 (2013): 824781. doi: https://doi.org/10.1155/2013/824781
Zedan M, Attia G, Zedan MM, Osman A, Abo-Elkheir N, Maysara N, Barakat T, Gamil N. Clinical asthma phenotypes and therapeutic responses. ISRN Pediatr. 2013 Mar 31;2013:824781. doi: 10.1155/2013/824781. Print 2013. PMID: 23606983; PMCID: PMC3628760.
Copy Download .nbib Format: NLM
Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice.

Advanced biomedical research

Kalantari E, Saeidi H, Kia NS, Tahergorabi Z, Rashidi B, Dana N, Khazaei M.
PMID: 24520550
Adv Biomed Res. 2013 Nov 30;2:83. doi: 10.4103/2277-9175.122498. eCollection 2013.

BACKGROUND: Notch signaling is a key factor for angiogenesis in physiological and pathological condition and γ-secretase is the regulator of Notch signaling. The main goal of this study was to assess the effect of (N-[N-(3,5-Diflurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester) DAPT, a...

Cite
Kalantari E, Saeidi H, Kia NS, et al. Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice. Adv Biomed Res. 2013;2:83doi: 10.4103/2277-9175.122498.
Kalantari, E., Saeidi, H., Kia, N. S., Tahergorabi, Z., Rashidi, B., Dana, N., & Khazaei, M. (2013). Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice. Advanced biomedical research, 283. https://doi.org/10.4103/2277-9175.122498
Kalantari, Elmira, et al. "Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice." Advanced biomedical research vol. 2 (2013): 83. doi: https://doi.org/10.4103/2277-9175.122498
Kalantari E, Saeidi H, Kia NS, Tahergorabi Z, Rashidi B, Dana N, Khazaei M. Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice. Adv Biomed Res. 2013 Nov 30;2:83. doi: 10.4103/2277-9175.122498. eCollection 2013. PMID: 24520550; PMCID: PMC3908495.
Copy Download .nbib Format: NLM
Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men.

Genes & nutrition

Pasman WJ, van Erk MJ, Klöpping WA, Pellis L, Wopereis S, Bijlsma S, Hendriks HF, Kardinaal AF.
PMID: 23595524
Genes Nutr. 2013 Sep;8(5):507-21. doi: 10.1007/s12263-013-0343-9. Epub 2013 Apr 18.

We aimed to explore whether vegetable consumption according to guidelines has beneficial health effects determined with classical biomarkers and nutrigenomics technologies. Fifteen lean (age 36 ± 7 years; BMI 23.4 ± 1.7 kg m(-2)) and 17 obese (age 40...

Cite
Pasman WJ, van Erk MJ, Klöpping WA, et al. Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men. Genes Nutr. 2013;8(5):507-21doi: 10.1007/s12263-013-0343-9.
Pasman, W. J., van Erk, M. J., Klöpping, W. A., Pellis, L., Wopereis, S., Bijlsma, S., Hendriks, H. F., & Kardinaal, A. F. (2013). Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men. Genes & nutrition, 8(5), 507-21. https://doi.org/10.1007/s12263-013-0343-9
Pasman, W J, et al. "Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men." Genes & nutrition vol. 8,5 (2013): 507-21. doi: https://doi.org/10.1007/s12263-013-0343-9
Pasman WJ, van Erk MJ, Klöpping WA, Pellis L, Wopereis S, Bijlsma S, Hendriks HF, Kardinaal AF. Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men. Genes Nutr. 2013 Sep;8(5):507-21. doi: 10.1007/s12263-013-0343-9. Epub 2013 Apr 18. PMID: 23595524; PMCID: PMC3755133.
Copy Download .nbib Format: NLM
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer.

Frontiers in pharmacology

Rak J.
PMID: 23508692
Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013.

In multicellular organisms both health and disease are defined by patterns of communication between the constituent cells. In addition to networks of soluble mediators, cells are also programed to exchange complex messages pre-assembled as multimolecular cargo of membraneous structures...

Cite
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013;4:21doi: 10.3389/fphar.2013.00021.
Rak, J. (2013). Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in pharmacology, 421. https://doi.org/10.3389/fphar.2013.00021
Rak, Janusz. "Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer." Frontiers in pharmacology vol. 4 (2013): 21. doi: https://doi.org/10.3389/fphar.2013.00021
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013. PMID: 23508692; PMCID: PMC3589665.
Copy Download .nbib Format: NLM
Finding biomarkers in non-model species: literature mining of transcription factors involved in bovine embryo development.

BioData mining

Turenne N, Tiys E, Ivanisenko V, Yudin N, Ignatieva E, Valour D, Degrelle SA, Hue I.
PMID: 22931563
BioData Min. 2012 Aug 29;5(1):12. doi: 10.1186/1756-0381-5-12.

BACKGROUND: Since processes in well-known model organisms have specific features different from those in Bos taurus, the organism under study, a good way to describe gene regulation in ruminant embryos would be a species-specific consideration of closely related species...

Cite
Turenne N, Tiys E, Ivanisenko V, et al. Finding biomarkers in non-model species: literature mining of transcription factors involved in bovine embryo development. BioData Min. 2012;5(1):12doi: 10.1186/1756-0381-5-12.
Turenne, N., Tiys, E., Ivanisenko, V., Yudin, N., Ignatieva, E., Valour, D., Degrelle, S. A., & Hue, I. (2012). Finding biomarkers in non-model species: literature mining of transcription factors involved in bovine embryo development. BioData mining, 5(1), 12. https://doi.org/10.1186/1756-0381-5-12
Turenne, Nicolas, et al. "Finding biomarkers in non-model species: literature mining of transcription factors involved in bovine embryo development." BioData mining vol. 5,1 (2012): 12. doi: https://doi.org/10.1186/1756-0381-5-12
Turenne N, Tiys E, Ivanisenko V, Yudin N, Ignatieva E, Valour D, Degrelle SA, Hue I. Finding biomarkers in non-model species: literature mining of transcription factors involved in bovine embryo development. BioData Min. 2012 Aug 29;5(1):12. doi: 10.1186/1756-0381-5-12. PMID: 22931563; PMCID: PMC3563503.
Copy Download .nbib Format: NLM
Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus.

Indian journal of nephrology

Torabinejad S, Mardani R, Habibagahi Z, Roozbeh J, Khajedehi P, Pakfetrat M, Banihashemi MA, Banihashemi SJ.
PMID: 22279336
Indian J Nephrol. 2012 Jan;22(1):5-12. doi: 10.4103/0971-4065.91179.

The purpose of this investigation was to assess the correlation of two biomarkers with the occurrence of renal flares in systemic lupus erythematosus (SLE). Urine levels of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor beta (TGF-β) were measured...

Cite
Torabinejad S, Mardani R, Habibagahi Z, et al. Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus. Indian J Nephrol. 2012;22(1):5-12doi: 10.4103/0971-4065.91179.
Torabinejad, S., Mardani, R., Habibagahi, Z., Roozbeh, J., Khajedehi, P., Pakfetrat, M., Banihashemi, M. A., & Banihashemi, S. J. (2012). Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus. Indian journal of nephrology, 22(1), 5-12. https://doi.org/10.4103/0971-4065.91179
Torabinejad, S, et al. "Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus." Indian journal of nephrology vol. 22,1 (2012): 5-12. doi: https://doi.org/10.4103/0971-4065.91179
Torabinejad S, Mardani R, Habibagahi Z, Roozbeh J, Khajedehi P, Pakfetrat M, Banihashemi MA, Banihashemi SJ. Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus. Indian J Nephrol. 2012 Jan;22(1):5-12. doi: 10.4103/0971-4065.91179. PMID: 22279336; PMCID: PMC3263065.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 57184 entries